Dr. Glick is a chemist and serial biotech entrepreneur with over 15 years’ experience in the biotech industry. He has founded several successful companies, including IFM Therapeutics. While CEO of IFM, the company progressed three programs from ideation to clinical development and executed several major transactions, including the sale of oncology assets to Bristol-Myers Squibb in a transaction valued more than $2.3 billion and the sale of an NLRP3 inhibitor program to Novartis for $1.6 billion. Prior to Odyssey, in 2020, he co-founded and launched Scorpion Therapeutics, where he played an instrumental role in the conception and building of the company. During his tenure as CEO, Scorpion grew to nearly 50 employees and raised $270 million across two financings. He is the author of more than 100 papers, the inventor on 54 issued U.S. patents, and the recipient of numerous awards recognizing his scientific contributions and accomplishments as a life science executive. Dr. Glick received his Ph.D. in Organic Chemistry from Columbia University and completed an NIH postdoctoral fellowship in Organic Chemistry at Harvard University.

Todd is an experienced biotech investor, is a Managing Director at MPM Capital and serves on a number of MPM portfolio company boards, including Aktis Oncology (Chairman), CODA Biotherapeutics, Entrada Therapeutics, Iconic Therapeutics, Repare Therapeutics (NASDAQ: RPTX), and Tetherex Pharmaceuticals. He previously served on the board of Semma Therapeutics, a potentially curative diabetes cell-therapy company founded by MPM and Doug Melton at Harvard, which was acquired by Vertex for $950M in 2019 in one of the largest ever preclinical M&A deals. He guided Selexys Pharmaceuticals to an acquisition by Novartis for $665M in 2016; Novartis launched the Selexys drug, Adakveo™ in late 2019 to treat sickle cell disease.

Todd has managed MPM’s strategic investment relationship with Novartis, which committed $200 million to over a dozen companies in the biotech and healthcare IT space under a variety of creative joint equity/strategic deal structures.

Prior to joining MPM in 1999, Todd’s career in the life science industry included business development at Genentech (Roche) and management consulting with Arthur D. Little. Todd earned his M.B.A. from Harvard Business School and his B.S. in Chemistry from the Massachusetts Institute of Technology.

Seth spent his first six years in the industry working in corporate business development and as a startup entrepreneur in high throughput biology, followed by 12 years as a growth strategy consultant for Fortune 500 biopharma.

In 1999, Seth founded Molecularware, winning the MIT 50K competition, and successfully exited in 2003. As Principal at TSG partners and Managing General Partner at Vectur LLC, Seth focused on corporate growth and buy-side M&A, as well as VC backed startup sell-side M&A.